Figure 5.
The effects of exosomes (EXO) on chronic AAD‐induced airway reactivity in the absence or presence of serelaxin (RLX). Shown is the SAL/CO versus OVA/NA‐induced airway resistance change from baseline (cmH2O ml–1·s−1) and from each of the treatment groups investigated against OVA/NA‐induced chronic AAD, in response to increasing concentrations of the bronchoconstrictor, methacholine; mean ± SEM from n = 8 mice per group. *P < 0.05, significantly different from the control group (SAL/CO); # P < 0.05, significantly different from the OVA/NA group; ¶ P < 0.05, significantly different from the OVA/NA + 5‐μg EXO‐treated group; † P < 0.05, significantly different from the OVA/NA + 25‐μg EXO‐treated group; § P < 0.05 significantly different from the OVA/NA + RLX‐treated group